Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


1811 - Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib


11 Sep 2017




Clinical Research;  Cancers in Adolescents and Young Adults (AYA);  GIST


Yukinori Kurokawa


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


Y. Kurokawa1, T. Doi2, A. Sawaki3, Y. Komatsu4, M. Ozaka5, T. Takahashi6, Y. Naito7, S. OKUBO8, T. Nishida9

Author affiliations

  • 1 Department Of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 565-0871 - Suita/JP
  • 2 Department Of Experimental Therapeutics, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 3 Department Of Medical Oncology, Fujita Health University Hospital, 470-1192 - Toyoake/JP
  • 4 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 5 Department Of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation For Cancer Research, 1358550 - Tokyo/JP
  • 6 Department Of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita/JP
  • 7 Division Of Developmental Therapeutics / Breast And Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 8 Gcmo Office, Taiho Pharmaceutical Co. Ltd., Tokyo/JP
  • 9 Director, National Cancer Center Hospital, 104-0045 - Tokyo/JP


Abstract 1811


Mutated KIT and PDGFRA in gastrointestinal stromal tumor (GIST) rely on HSP90 for their functional stability; therefore, HSP90 is a rational therapeutic target in treating GIST in patients (pts) acquired resistance to approved tyrosine kinase inhibitors. TAS-116 is an oral non-ansamycin, non-purine, non-resorcinol, highly selective inhibitor of HSP90α/β with antitumor activity in an imatinib-resistant human GIST xenograft mouse model. In a phase I study, TAS-116 demonstrated the acceptable safety and the efficacy signs in radiological imaging in pts with GIST including 1 partial response. Here, we conducted a phase II study to evaluate the safety and efficacy of TAS-116 in metastatic or unresectable GIST refractory to standard therapies.


This was a phase II, open label, single-arm, multi-center study. The key eligibility criteria were histologically confirmed GIST refractory to imatinib, sunitinib, and regorafenib; a measurable lesion per RECIST ver. 1.1; and adequate organ function. Pts received 160 mg/day TAS-116 on a 5-days-on/2-days-off schedule. The primary endpoint was progression-free survival (PFS); secondary endpoints included objective response rate, disease control rate, overall survival, and adverse events. An independent central review (ICR) committee assessed all responses. Sample size was 40 for full analysis set.


From 12 May 2016 to 26 April 2017, 40 pts were enrolled in this study. The numbers of prior treatments was 3 in 24 pts, 4 in 9 pts, and ≥5 in 7 pts. In 34 pts evaluated as of 26 April 2017, the most common adverse events were diarrhea (82%), anorexia (50%), increased serum creatinine (44%), and eye disorders (21%). All eye disorders recovered or resolved following dose interruption, and were limited to Grade 1. There were no treatment-related deaths. According to ICR, median PFS was 4.5 months (95% CI, 2.9–6.1 months). Although none had a partial response, 27 out of 34 pts (79%) had stable disease for ≥6 weeks.


TAS-116 was well tolerated and the initial efficacy results in a ≥ 4th-line treatment setting for metastatic or unresectable GIST, are encouraging. Updated data will be presented at the meeting.

Clinical trial identification


Legal entity responsible for the study

Taiho Pharmaceutical co., LTD.


Taiho Pharmaceutical co., LTD.


Y. Kurokawa: Honoraria: Taiho Pharmaceutical, Yakult Honsha, Eli Lilly, Novartis, Pfizer, Chugai Pharma. T. Doi: Consulting/advisory role: Eli Lilly, Chugai, Kyowa Hakko Kirin, Novartis, MSD, Daiichi Sankyo, Amgen. Research funding: Taiho, Novartis, Merck Serono, Astellas, MSD, Janssen, Boehringer Ingelheim, Takeda, Pfizer, Eli Lilly, Sumitomo Group, Chugai, Bayer, Kyowa Hakko Kirin, Daiichi Sankyo, Celgene. A. Sawaki: Speakers’ Bureau: Novartis, Pfizer, Bayer, Taiho Pharmaceutical, Lilly, Eisai, Chugai Pharma, Yakult, Honsha, Research funding: Taiho Pharmaceutical. Y. Komatsu: Speakers’ Bureau: Taiho, Eli Lilly, Chugai Pharma, Merck Serono, Novartis, Pfizer, Bayer. Honoraria: Novartis, Pfizer, Bayer Research funding: Taiho, Eli Lilly, MSD, Ono Pharmaceutical, Novartis, Bayer, Chugai Pharma, Yakult Honsha. M. Ozaka: Honoraria: Taiho Pharmaceutical, Pfizer, Novartis, Bayer, Yakult Honsha. T. Takahashi: Speakers’ Bureau: Novartis, Pfizer, Bayer, SBI pharma. Research funding: SBI Pharma. Y. Naito: Speakers’ Bureau: Eisai, Chugai Pharma, Taiho Phamaceutical, Novartis, Eli Lilly, Meiji Seika Pharma, Bayer, Roche Diagnostics K.K. Research funding: Merck Serono, AstraZeneca, Eli Lilly, Nippon Kayaku. S. Okubo: Employment: Taiho Pharmaceutical Patents, Royalties, other intellectual property: Taiho Pharmaceutical. T. Nishida: Honoraria: Pfizer, Novartis, Bayer, Eisai, Sysmex.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.